An interventional study of Transcranial Direct Current Stimulation in Anxiety Disorders and Social Phobia, sponsored by Laureate Institute for Brain Research, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-09-01.
Sponsored by Laureate Institute for Brain Research, Inc. · Not applicable, Interventional, and Basic science
Among 187 studies in Phobia, Social with a site in United States — 23 open to participants now, 29 under way, 1 of them phase 3. Phobia, Social · United States.
Among the 187 studies in Phobia, Social with a site in United States, this one is the 94th largest by enrollment of the 178 interventional ones that give a count, is one of 11 that started in 2017, is one of 100 with no phase, and was the 106th registered.
368 studies on the registry are indexed under Phobia, Social; 59 are open to participants now.
Browse Phobia, Social studies →23 of the 187 studies in Phobia, Social with a site in United States are open now. Recruiting first, the newest first:
Jason Careri · Sites in United States
Ages 18–65
Andrew Wiese · Sites in United States
Ages 7–17
Newleos Therapeutics, Inc. · Sites in United States
Ages 18–65
Bradley Hospital · Sites in United States
Ages 5–18
Ohio State University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 46 Phobia, Social studies recruiting now, 10 (22%) set no upper age limit and 34 (74%) stop at 75 or younger; 14 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 34 · Phase 3 21 · Phase 4 18
First in 1998; this study’s year is marked. 11 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 76 across 339 interventional studies indexed under Phobia, Social.
Median enrollment 64 across the 178 interventional studies, 184 across the 8 observational. Of the 146 that completed or were terminated, 59 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 187 have an industry lead sponsor. The 10 most frequent:
Laureate Institute for Brain Research, Inc. is the lead sponsor of 54 studies on the registry; 11 are open to participants now.
Laureate Institute for Brain Research, Inc. has 4 studies filed under Phobia, Social — fewer than ten, so there is no comparison to draw.
13 of the studies in Phobia, Social with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07221578Phase 3Vanda PharmaceuticalsStudy to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder | 2026-12 |
| NCT04663724New York State Psychiatric InstituteComputer - Based Treatment for Social Anxiety Disorder | 2026-11-30 |
| NCT07589621Florida State UniversitySafety Behavior Fading Versus Progressive Muscle Relaxation for Appearance Concerns | 2026-12 |
| NCT05467683Jasper A. SmitsCO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy | 2026-12-01 |
| NCT07028216Georgetown UniversityMindful Self-compassion for Anxiety and Depression: Impact of Delivery Method | 2026-12-17 |
Add all 13 to your calendar (.ics) → With an account.
Among the 187 studies in Phobia, Social with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Emerging neuroimaging studies have shown that the cerebellum contributes to different aspects of timing, prediction, learning, and extinction of conditioned responses to aversive stimuli, factors that may be relevant to the success of exposure based behavioral therapy. Our goals are to determine the cerebellar contributions to fear extinction by attempting to modulate key pathways in this process by theta burst stimulation. The long term goal is to lay the foundation for future studies in which neuromodulation is used to augment exposure therapy.
Participants in this study will undergo an assessment for past history and present symptoms of mood, anxiety, trauma, substance abuse, and eating disorders. Safety screening for functional MRI (fMRI) and repetitive transcranial magnetic stimulation (rTMS) will be performed prior to enrollment.
Phase 1 of the study involves two visits. The first visit involves undergoing an fMRI scan and a motor thresholding procedure for rTMS. A clinical assessment will be performed for the above symptoms, or a recap of symptoms if the participant had been previously assessed at our institute.
The second visit involves a fear conditioning session performed in the fMRI scanner followed by one session of rTMS over either a cerebellar or occipital lobe (control) target. This will be immediately followed by a fear extinction phase, also in the fMRI scanner. The participant will return in 24hours to determine consolidation of the fear extinction process.
Phase 2 is similar to Phase 1, except that each participant will undergo two sessions of the fear conditioning and fear extinction phases while undergoing an fMRI scan. In one session, they will receive rTMS over a cerebellar target. In the other session, they will receive rTMS over a control site. These sessions will be separated by at least 1 week.
The participants will then undergo 10 weeks of exposure therapy for social phobia. The goal is to determine whether neuroplasticity related to cerebellar stimulation can predict the response to exposure therapy.
368 studies on the registry are indexed under Phobia, Social; 59 are open to participants now.
This study's enrollment of 60 is below the median of 76 across 339 interventional studies indexed under Phobia, Social.
Browse Phobia, Social studies →Laureate Institute for Brain Research, Inc. is the lead sponsor of 54 studies on the registry; 11 are open to participants now.
Compared within Phobia, Social, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Anodal tDCS will be performed over bilateral cerebellar hemispheres for 20-minutes.
Device: Transcranial Direct Current Stimulation
Cathodal tDCS will be performed over bilateral cerebellar hemispheres for 20-minutes.
Device: Transcranial Direct Current Stimulation
Sham tDCS will be performed over bilateral cerebellar hemispheres for 20-minutes.
Device: Transcranial Direct Current Stimulation
tDCS is a non-invasive form of neuromodulation in which direct current is administered placed over a brain region of interest to induce physiological changes such as inhibition or excitation over that region.
Also known as: tDCS
Activation of ventromedial prefrontal cortex after cerebellar stimulation
Activation of vmPFC
Time frame: Phase 1, Years 1-3
Change in resting state connectivity between vmPFC and cerebellar stimulation target
Change in resting state connectivity between vmPFC and cerebellum after cerebellar stimulation
Time frame: Phase 1, Years 1-3
Baseline cerebellar-cerebral connectivity prediction of exposure therapy outcomes
Baseline cerebellar-cerebral connectivity prediction of exposure therapy outcomes
Time frame: Phase 2, Years 3-5
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2017 to primary completion in Dec 2019, 28 months.
Of 142 non-industry interventional studies with no phase under Phobia, Social, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 44. This study's 28 months is close to that.
Counting every sponsor, half of 148 studies reached it within 28 months; a quarter within 14 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Laureate Institute for Brain Research, Inc.